Cideb Regulates Diet-Induced Obesity, Liver Steatosis, and Insulin Sensitivity by Controlling Lipogenesis and Fatty Acid Oxidation
Diabetes2007Vol. 56(10), pp. 2523–2532
Citations Over TimeTop 10% of 2007 papers
Abstract
Our data demonstrate that Cideb is a novel important regulator in lipid metabolism in the liver. Cideb may represent a new therapeutic target for the treatment of obesity, diabetes, and liver steatosis.
Related Papers
- → Genetic control ofde novolipogenesis: role in diet-induced obesity(2010)405 cited
- → Fatty Acid Synthase Activity in Tumor Cells(2008)41 cited
- Research Progress in the Fatty Acid Synthase Gene(2008)
- → Review for "Inhibition of fatty acid synthase with <scp>FT</scp> ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with <scp>NAFLD</scp> non‐alcoholic fatty liver disease: results from two early phase randomized trials"(2020)
- → Review for "Inhibition of fatty acid synthase with <scp>FT</scp> ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with <scp>NAFLD</scp> non‐alcoholic fatty liver disease: results from two early phase randomized trials"(2020)